Biomet Offers $280 Mil. For J&J’s DePuy Trauma Biz; Bid Facilitates Synthes Deal
J&J expects the divestiture to reduce regulatory barriers to its pending $21 billion Synthes acquisition.
J&J expects the divestiture to reduce regulatory barriers to its pending $21 billion Synthes acquisition.